Abstract
DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439–446, 2016. © 2016 Wiley Periodicals, Inc.
Author supplied keywords
Cite
CITATION STYLE
Zhu, H., Aryal, D. K., Olsen, R. H. J., Urban, D. J., Swearingen, A., Forbes, S., … Hochgeschwender, U. (2016). Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice. Genesis, 54(8), 439–446. https://doi.org/10.1002/dvg.22949
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.